Research progress of immunotherapy in esophageal squamous cell carcinoma / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 429-432, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-907557
ABSTRACT
With the development of immunotherapy in clinical application, immunotherapy also takes advantage in esophageal squamous cell carcinoma (ESCC). Immune checkpoint inhibitors such as programmed death-1 (PD-1) and its ligand PD-L1 and cytotoxic T lymphocyte antigen-4 show significant antitumor activity and safety in immunotherapy for patients with advanced ESCC.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of International Oncology
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS